Terms of Reference for the Technical Advisory Group on Building an Innovation Ecosystem for Public Health (TAG-BIEFPH) in the World Health Organization Regional Office for Europe

The WHO European Region faces a myriad of complex health challenges, ranging from the profound impact of climate change to the escalating threat of antimicrobial resistance (AMR) and the rising burden of noncommunicable diseases (NCDs). Despite these challenges, the region is endowed with significant innovation capacities that encompass scientific breakthroughs, technological advancements, and innovative healthcare models. However, the full potential of these innovations is yet to be tapped to benefit public health.

In light of these circumstances, there is a critical need to reimagine how innovation can be strategically positioned to serve public health effectively. The Technical Advisory Group for Building an Innovation Ecosystem for Public Health (TAG-BIEFPH) is envisaged to play a pivotal role by providing expert guidance and recommendations to navigate the complexities of fostering innovation within the public health sector. The TAG's expertise will be instrumental in addressing the WHO/Europe's pressing health challenges, seizing opportunities for innovation to enhance service delivery, drive policy development, and bolster overall public health impact. By leveraging the diverse landscape of public health innovation, encompassing social, scientific and technological advancements, and policy reforms, the TAG will work towards shaping a comprehensive and sustainable innovation ecosystem that aligns with the evolving public health needs of populations across the WHO European Region.

The Advisory Group (the AG) will act as an advisory body to WHO in this field.

I. Functions

In its capacity as an advisory body to WHO, the AG shall have the following functions:

1. Policy analysis for innovation
   - Conduct comprehensive policy analysis to assess the coherence of existing policies related to innovation in public health.
   - Identify areas for policy improvement and recommend adjustments to enhance the innovation ecosystem.
   - Review regulatory frameworks, funding mechanisms, and collaboration structures to create an enabling environment for innovation.

2. Identifying innovation for scale-up
   - Map public health innovations with potential for significant impact on health outcomes.
   - Develop a strategy for scaling up selected innovations, considering feasibility, sustainability, and scalability across diverse settings.
   - Assess resource availability, stakeholder engagement, and adaptability to different contexts for successful scaling.
3. Country capacity needs for innovation
- Advice WHO on enhancing problem identification and collaboration between innovation hubs and public health authorities to define specific public health issues.
- Evaluate countries' innovation capacity to determine strengths, weaknesses, and readiness for innovation.
- Develop tailored capacity-building needs, including curriculum, training materials, and tools for problem statement generation.

4. Establishing governance mechanisms for innovation. Advice WHO on:
- Definition of a governance framework to organize national innovation efforts effectively.
- Clarification of roles, responsibilities, and coordination mechanisms among stakeholders involved in scaling up innovations.
- Ensuring transparency, accountability, and effective communication channels within the governance structure.

5. Monitoring and evaluation mechanisms
- Develop monitoring and evaluation mechanisms to track the progress of innovation scale-up.
- Develop indicators to measure the impact of innovations on health outcomes
- Develop data-driven models to optimize implementation, make informed decisions, and address challenges during the scale-up process.

6. Strategic recommendations
- Develop recommendations that support the development of a Strategy for harnessing health innovation in the WHO European Region

II. Composition

1. The AG shall have up to 15 members¹, who shall serve in their personal capacities to represent the broad range of disciplines relevant to innovation in public health. In the selection of the AG members, consideration shall be given to attaining an adequate distribution of technical expertise, geographical representation and gender balance.

2. Members of the AG, including the Chairperson, shall be selected and appointed by WHO following an open call for experts. The Chairperson's functions include the following:
   - to chair the meeting of the AG;
   - to liaise with the WHO Secretariat between meetings.

   In appointing a Chairperson, consideration shall be given to gender and geographical representation.

3. Members of the AG shall be appointed to serve for a period of 2 years and shall be eligible for reappointment. A Chairperson is eligible for reappointment as a member of the AG, but is only permitted to serve as Chairperson for one term. Their appointment and/or

¹ Members serve as full participants and partake in the deliberations and the adoption of the recommendations of the meeting in which they are involved.
designation as Chairperson may be terminated at any time by WHO if WHO's interest so requires or, as otherwise specified in these terms of reference or letters of appointment. Where a member’s appointment is terminated, WHO may decide to appoint a replacement member.

4. AG members must respect the impartiality and independence required of WHO. In performing their work, members may not seek or accept instructions from any Government or from any authority external to the Organization. They must be free of any real, potential or apparent conflicts of interest. To this end, proposed members/members shall be required to complete a declaration of interests form and their appointment, or continuation of their appointment, shall be subject to the evaluation of completed forms by the WHO Secretariat, determining that their participation would not give rise to a real, potential or apparent conflict of interest.

5. Following a determination that a proposed member’s participation in the AG would not give rise to a real, potential or apparent conflict of interest, the proposed member will be sent a letter inviting them to be a member of the AG. Their appointment to the AG is subject to WHO receiving the countersigned invitation letter and letter of agreement. Notwithstanding the requirement to complete the WHO declaration of interest form, AG members have an ongoing obligation to inform the WHO of any interests real or perceived that may give raise to a real, potential or apparent conflict of interest.

6. As contemplated in paragraph II.4 above, WHO may, from time to time, request AG members to complete a new declaration of interest form. This may be before a AG meeting or any other AG-related activity or engagement, as decided by WHO. Where WHO has made such a request, the AG member’s participation in the AG activity or engagement is subject to a determination that their participation would not give rise to a real, potential or apparent conflict of interest.

7. Where a AG member is invited by WHO to travel to an in-person AG meeting, WHO shall, subject to any conflict of interest determination as set out in paragraph II.6 above, issue a letter of appointment as a temporary adviser and accompanying memorandum of agreement (together with a ‘Temporary Adviser Letter’). WHO shall not authorize travel by an AG member, until it receives a countersigned Temporary Adviser Letter.

8. AG members do not receive any remuneration from the Organization for any work related to the AG. However, when attending in-person meetings at the invitation of WHO, their travel cost and per diem shall be covered by WHO in accordance with the applicable WHO rules and policies.

III. Operation

1. The AG shall normally meet at least once each year. However, WHO may convene additional meetings. AG meetings may be held in person (at WHO headquarters in Geneva or another location, as determined by WHO) or virtually, via video or teleconference.
AG meetings may be held in open and/or closed session, as decided by the Chairperson in consultation with WHO.

(a) Open sessions: Open sessions shall be convened for the sole purpose of the exchange of non-confidential information and views, and may be attended by Observers (as defined in paragraph III.3 below).

(b) Closed sessions: The sessions dealing with the formulation of recommendations and/or advice to WHO shall be restricted to the members of the AG and essential WHO Secretariat staff.

2. The quorum for AG meetings shall be two thirds of the members.

3. WHO may, at its sole discretion, invite external individuals from time to time to attend the open sessions of an advisory group, or parts thereof, as “observers”. Observers may be invited either in their personal capacity, or as representatives from a governmental institution / intergovernmental organization, or from a non-State actor. WHO will request observers invited in their personal capacity to complete a confidentiality undertaking and a declaration of interests form prior to attending a session of the advisory group. Invitations to observers attending as representatives from non-State actors will be subject to WHO internal due diligence and risk assessment including conflict of interest considerations in accordance with the Framework for engagement with non-State actors (FENSA). Observers invited as representatives may also be requested to complete a confidentiality undertaking. Observers shall normally attend meetings of the AG at their own expense and be responsible for making all arrangements in that regard.

At the invitation of the Chairperson, observers may be asked to present their personal views and/or the policies of their organization. Observers will not participate in the process of adopting recommendations of the AG.

4. The AG may decide to establish smaller working groups (sub-groups of the AG) to work on specific issues. Their deliberations shall take place via teleconference or video-conference. For these sub-groups, no quorum requirement will apply; the outcome of their deliberations will be submitted to the AG for review at one of its meetings.

5. AG members are expected to attend meetings. If a member misses two consecutive meetings, WHO may end his/her appointment as a member of the AG.

6. Reports of each meeting and a yearly report shall be submitted by the AG to WHO (the Assistant Director-General of the responsible Cluster). All recommendations from the AG are advisory to WHO, who retains full control over any subsequent decisions or actions regarding any proposals, policy issues or other matters considered by the AG.

7. The AG shall normally make recommendations by consensus. If, in exceptional circumstances, a consensus on a particular issue cannot be reached, minority opinions will be reflected in the meeting report.
8. [Active participation is expected from all AG members, including in working groups, teleconferences, and interaction over email.] AG members may, in advance of AG meetings, be requested to review meeting materials and to provide their views for consideration by the AG.

9. WHO shall determine the modes of communication by the AG, including between WHO and the AG members, and the AG members among themselves.

10. AG members shall not speak on behalf of, or represent, the AG or WHO to any third party.

IV. Secretariat

WHO shall provide the secretariat for the AG, including necessary scientific, technical, administrative and other support. In this regard, the WHO Secretariat shall provide the members in advance of each meeting with the agenda, working documents and discussion papers. Distribution of the aforesaid documents to Observers will be determined by the WHO Secretariat. [The meeting agenda shall include details such as: whether a meeting, or part thereof, is closed or open; and whether Observers are permitted to attend.]

V. Information and documentation

1. Information and documentation to which members may gain access in performing AG related activities shall be considered as confidential and proprietary to WHO and/or parties collaborating with WHO. In addition, by counter signing the letter of appointment and the accompanying terms and conditions referred to in section II(5) above, AG members undertake to abide by the confidentiality obligations contained therein and also confirm that any and all rights in the work performed by them in connection with, or as a result of their AG-related activities shall be exclusively vested in WHO.

2. AG members and Observers shall not quote from, circulate or use AG documents for any purpose other than in a manner consistent with their responsibilities under these Terms of Reference.

3. WHO retains full control over the publication of the reports of the AG, including deciding whether or not to publish them.